Astec LifeSciences Latest Share Price (ASTEC)
TODAY IN ONE LINE
ASTEC rose 1.0% on light volume, in line with Nifty's 0.2% move, supported by recent strong earnings.
With a market cap of ₹1,341.43 Cr., it trades at a P/E of -20.22. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
Astec LifeSciences flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Quarterly OutperformanceLatest quarter Sales up 32.7% and Profit up 51.8%
- ●High Promoter HoldingPromoters hold 72.0% skin-in-the-game
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
No red flags identified
Latest Astec LifeSciences News
What changed recently?
Recent events, corporate actions, and announcements.
Astec LifeSciences Limited valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Astec LifeSciences Limited, framed against the sector median so the premium or discount is obvious at a glance.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
Astec LifeSciences Limited technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for Astec LifeSciences Limited — derived from the latest tape, not yesterday's close.
Astec LifeSciences Limited last traded at ₹598.8 with an intraday range of ₹584.25–₹608.9 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹598.80| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 659.68 | +60.88 | +10.17% |
| R3 | 635.03 | +36.23 | +6.05% |
| R2 | 621.97 | +23.17 | +3.87% |
| R1 | 610.38 | +11.58 | +1.93% |
| PIVOT | 597.32 | -1.48 | -0.25% |
| CURRENT | 598.80 | — | — |
| S1 | 585.73 | -13.07 | -2.18% |
| S2 | 572.67 | -26.13 | -4.36% |
| S3 | 561.08 | -37.72 | -6.30% |
| S4 | 536.43 | -62.37 | -10.42% |
ASTEC is trading Above CPR, indicating Bullishness
CPR is Average
Day's range: ₹590–₹596
Trading Inside opening range
Astec LifeSciences Limited financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for Astec LifeSciences Limited — consolidated or standalone — with margins, YoY growth and key ratios inline.
Astec LifeSciences Limited reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹1,341.43 Cr. and reported EPS of ₹-29.31.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 381 | 448 ▲ 17.5% |
| Sales Growth YoY %Derived | -16.78% | 17.53% |
| Other Income | 6 | 5 ▼ 9.9% |
| Total Income | 387 | 453 ▲ 17.1% |
| 297 | 298 ▲ 0.5% | |
| Gross ProfitDerived | 84 | 150 ▲ 77.5% |
| Gross Margin %Derived | 22.13% | 33.41% |
| 151 | 154 ▲ 2.4% | |
| EBITDA (Operating Profit)Derived | -66 | -5 ▲ 93.2% |
| OPM %Derived | -17.36% | -1.01% |
| 80 | 77 ▼ 3.8% | |
| Profit Before Tax (PBT) | -141 | -81 ▲ 42.5% |
| -6 | -0 ▲ 98.0% | |
| Effective Tax %Derived | 4.45% | 0.15% |
| Total Profit for Period | -135 | -81 ▲ 40.0% |
| Less: Non-controlling Interests | 0 | 0 ▲ 1.5% |
| Net Profit (Owner's PAT)Derived | -135 | -81 ▲ 40.0% |
| Net Profit Margin %Derived | -35.34% | -18.06% |
| PAT Growth YoY %Derived | -187.14% | 39.95% |
| Earnings Per Share (EPS ₹) | -60.12 | -36.31 ▲ 39.6% |
| Diluted Shares Outstanding (Cr) | 2 | 2 ▼ 0.6% |
| Other Comprehensive Income (Net of Tax) | 0 | 0 ▲ 165.7% |
| Total Expenses (incl. D&A & Interest) | 528 | 534 ▲ 1.2% |
| Material Cost % of RevenueDerived | 65.27% | 60.35% |
| Employee Cost % of RevenueDerived | 16.03% | 14.04% |
| Other Cost % of RevenueDerived | 23.46% | 20.38% |
| Interest Coverage (x)Derived | -3.00x | -1.43x |
| Period | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 371 | 431 ▲ 16.2% | 523 ▲ 21.3% | 555 ▲ 6.2% | 677 ▲ 21.9% | 628 ▼ 7.2% | 458 ▼ 27.1% | 381 ▼ 16.8% | 448 ▲ 17.5% | |
| Sales Growth YoY %Derived | — | 16.19% | 21.28% | 6.17% | 21.93% | -7.15% | -27.06% | -16.78% | 17.53% | |
| Other Income | 8 | 11 ▲ 37.6% | 12 ▲ 7.0% | 8 ▼ 33.6% | 10 ▲ 32.2% | 13 ▲ 24.8% | 6 ▼ 56.8% | 6 ▼ 0.3% | 5 ▼ 9.9% | |
| Total Income | 379 | 442 ▲ 16.7% | 535 ▲ 20.9% | 563 ▲ 5.3% | 687 ▲ 22.1% | 641 ▼ 6.7% | 464 ▼ 27.7% | 387 ▼ 16.6% | 453 ▲ 17.1% | |
235 | 279 ▲ 18.9% | 339 ▲ 21.1% | 342 ▲ 1.0% | 387 ▲ 13.1% | 401 ▲ 3.7% | 319 ▼ 20.4% | 297 ▼ 7.0% | 298 ▲ 0.5% | ||
| Gross ProfitDerived | 136 | 151 ▲ 11.5% | 184 ▲ 21.6% | 213 ▲ 15.6% | 290 ▲ 36.1% | 227 ▼ 21.7% | 139 ▼ 38.8% | 84 ▼ 39.3% | 150 ▲ 77.5% | |
| Gross Margin %Derived | 36.62% | 35.14% | 35.22% | 38.36% | 42.83% | 36.12% | 30.32% | 22.13% | 33.41% | |
67 | 75 ▲ 11.8% | 99 ▲ 32.0% | 101 ▲ 2.4% | 136 ▲ 34.0% | 151 ▲ 11.0% | 145 ▼ 3.9% | 151 ▲ 4.0% | 154 ▲ 2.4% | ||
| EBITDA (Operating Profit)Derived | 69 | 76 ▲ 11.2% | 85 ▲ 11.4% | 112 ▲ 31.0% | 154 ▲ 38.1% | 76 ▼ 50.5% | -6 ▼ 107.8% | -66 ▼ 1019.8% | -5 ▲ 93.2% | |
| OPM %Derived | 18.55% | 17.75% | 16.30% | 20.10% | 22.77% | 12.14% | -1.29% | -17.36% | -1.01% | |
29 | 32 ▲ 7.6% | 36 ▲ 12.7% | 30 ▼ 15.0% | 43 ▲ 42.8% | 54 ▲ 25.2% | 61 ▲ 13.1% | 80 ▲ 30.8% | 77 ▼ 3.8% | ||
| Profit Before Tax (PBT) | 56 | 56 ▲ 0.3% | 61 ▲ 9.7% | 89 ▲ 45.2% | 121 ▲ 36.0% | 35 ▼ 71.1% | -62 ▼ 276.7% | -141 ▼ 128.3% | -81 ▲ 42.5% | |
21 | 20 ▼ 2.6% | 14 ▼ 31.3% | 24 ▲ 73.6% | 31 ▲ 30.2% | 9 ▼ 70.1% | -15 ▼ 258.8% | -6 ▲ 57.7% | -0 ▲ 98.0% | ||
| Effective Tax %Derived | 37.11% | 36.02% | 22.53% | 26.95% | 25.79% | 26.76% | 24.06% | 4.45% | 0.15% | |
| Total Profit for Period | 35 | 36 ▲ 2.1% | 48 ▲ 32.9% | 65 ▲ 36.9% | 90 ▲ 38.1% | 26 ▼ 71.5% | -47 ▼ 283.2% | -135 ▼ 187.3% | -81 ▲ 40.0% | |
| Less: Non-controlling Interests | 0 | 0 ▼ 78.6% | 0 ▼ 44.1% | 0 ▲ 24.4% | 0 ▲ 20.6% | 0 ▲ 20.8% | 0 ▲ 32.8% | 0 ▲ 5.7% | 0 ▲ 1.5% | |
| Net Profit (Owner's PAT)Derived | 35 | 36 ▲ 2.4% | 48 ▲ 32.9% | 65 ▲ 36.9% | 90 ▲ 38.1% | 26 ▼ 71.5% | -47 ▼ 283.6% | -135 ▼ 187.1% | -81 ▲ 40.0% | |
| Net Profit Margin %Derived | 9.41% | 8.29% | 9.09% | 11.72% | 13.28% | 4.07% | -10.24% | -35.34% | -18.06% | |
| PAT Growth YoY %Derived | — | 2.39% | 32.95% | 36.91% | 38.14% | -71.55% | -283.57% | -187.14% | 39.95% | |
| Earnings Per Share (EPS ₹) | 15.64 | 15.99 ▲ 2.2% | 21.24 ▲ 32.8% | 29.07 ▲ 36.9% | 40.12 ▲ 38.0% | 11.41 ▼ 71.6% | -20.94 ▼ 283.5% | -60.12 ▼ 187.1% | -36.31 ▲ 39.6% | |
| Diluted Shares Outstanding (Cr) | 2 | 2 ▲ 0.1% | 2 ▲ 0.1% | 2 ▲ 0.1% | 2 ▲ 0.1% | 2 ▲ 0.0% | 2 ▲ 0.0% | 2 ▲ 0.0% | 2 ▼ 0.6% | |
| Other Comprehensive Income (Net of Tax) | -0 | 0 ▲ 167.3% | -0 ▼ 187.7% | -0 ▼ 7.9% | -0 ▲ 96.1% | -0 ▼ 2930.6% | -1 ▼ 168.5% | 0 ▲ 129.7% | 0 ▲ 165.7% | |
| Total Expenses (incl. D&A & Interest) | 323 | 386 ▲ 19.5% | 473 ▲ 22.5% | 474 ▲ 0.1% | 566 ▲ 19.5% | 606 ▲ 7.1% | 526 ▼ 13.3% | 528 ▲ 0.4% | 534 ▲ 1.2% | |
| Material Cost % of RevenueDerived | 60.46% | 68.47% | 63.80% | 62.10% | 65.75% | 73.36% | 69.58% | 65.27% | 60.35% | |
| Employee Cost % of RevenueDerived | 5.85% | 5.82% | 5.73% | 6.91% | 7.44% | 8.32% | 13.48% | 16.03% | 14.04% | |
| Other Cost % of RevenueDerived | 12.21% | 11.57% | 13.20% | 11.34% | 12.62% | 15.67% | 18.13% | 23.46% | 20.38% | |
| Interest Coverage (x)Derived | 5.08x | 4.62x | 4.92x | 18.08x | 13.22x | 2.06x | -1.67x | -3.00x | -1.43x |
Astec LifeSciences segment analysis : revenue and profit mix.
Disclosed business segments at Astec LifeSciences with their share of revenue and profit, switchable between consolidated and standalone reporting.
Astec LifeSciences discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for Astec LifeSciences Limited.
Our AI distills the core fundamental drivers supporting Astec LifeSciences Limited, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
Astec LifeSciences Limited's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Strong promoter holding at 71.97% signals long-term commitment and insider confidence.
TTM revenue growth of 32.7% demonstrates robust top-line momentum despite profitability challenges.
Diversified product portfolio spanning fungicides, herbicides, insecticides, and specialty chemicals.
Export presence across 17 countries provides geographic diversification and revenue resilience.
Subsidiary of Godrej Agrovet offers resource leverage and market access advantages.
Key Risks.
Operating margin of -1.01% and net margin of -18.06% indicate severe profitability deterioration.
Latest quarterly EPS of -7.76 with negative ROE of -25.20% erodes shareholder value significantly.
Net debt of ₹438.89 Cr at 1.13x equity strains liquidity; current ratio 0.88 below safety threshold.
Operating cash flow negative ₹80.59 Cr signals persistent cash burn and poor earnings quality.
Zero dividend yield and no cash generation per share limit investor returns substantially.
Flip Conditions.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.65. Balance sheet risk re-prices growth multiples fast.
Astec LifeSciences Limited peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Astec LifeSciences Limited is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
Astec LifeSciences Limited chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for Astec LifeSciences Limited — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
Astec LifeSciences Limited delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Astec LifeSciences Limited over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Astec LifeSciences Limited stood at 58.4% of traded volume, against a 20-day average of 47.3%.
Astec LifeSciences announcements: results, concalls, ratings, M&A.
Filings Astec LifeSciences sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Astec LifeSciences files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 103 documents below.
Copy of Newspaper Publication
Astec LifeSciences Limited has informed the Exchange about Copy of Newspaper Publication
Updates
Astec LifeSciences Limited has informed the Exchange regarding 'Adoption of Annual Report 2025-26 by the Shareholders at the AGM held on 31st July,…
Shareholders meeting
Astec LifeSciences Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on July 31, 2026. Further, the company has…
General Updates
Astec LifeSciences Limited has informed the Exchange about General Updates
Press Release
Astec LifeSciences Limited has informed the Exchange regarding a press release dated July 31, 2026, titled "ASTEC: Astec LifeSciences Limited has…
Investor decks & rating reports.
Astec LifeSciences dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Astec LifeSciences has declared, sequenced by announce and record date.
Astec LifeSciences corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
Astec LifeSciences insider trading: promoter and management activity.
Promoter, director and designated-employee transactions in Astec LifeSciences as reported to SEBI — buying and selling signals from the people who know the business best.
Astec LifeSciences insider activity below tracks 4 reported promoter, director and designated-employee transactions under SEBI Regulation 7(2).
| Insider | Category | Txn Date | Action | Quantity | Value (₹) | Price |
|---|---|---|---|---|---|---|
| Tanya Dubash | Insider | 01 Jan 2025 | buy | +1.35 L | ₹14.78 Cr. | ₹1,094.96 |
| Pirojsha Godrej | Insider | 01 Jan 2025 | buy | +1.35 L | ₹14.77 Cr. | ₹1,094.96 |
| Nisaba Godrej | Insider | 01 Jan 2025 | buy | +1.35 L | ₹14.78 Cr. | ₹1,094.96 |
| Nadir Godrej | Insider | 01 Jan 2025 | buy | +4.05 L | ₹44.32 Cr. | ₹1,094.96 |
About Astec LifeSciences Limited: business, sector, key facts.
What Astec LifeSciences Limited does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Astec LifeSciences Limited operates in the Pesticides & Agrochemicals industry under the Chemicals sector, listed as NSE: ASTEC, BSE: 533138.
Astec LifeSciences Limited is a prominent Indian company specializing in the manufacturing and distribution of agrochemical active ingredients and pharmaceutical intermediates. Its primary focus lies within the agrochemical sector, providing a diverse range of products designed to enhance agricultural yields and protect crops from various diseases and pests. A significant portion of their business involves the production and sale of triazole fungicides, utilized extensively in treating field crops against a variety of fungal infections.
The company's fungicide offerings are tailored to address specific crop needs. They provide foliar treatments to combat diseases such as scab, powdery mildew, shot-hole, blossom blight, and rust. Furthermore, Astec LifeSciences supplies seed treatments for crops like cotton, maize, barley, rice, and wheat, safeguarding seeds and soil from various pathogens. Their product range even extends to post-harvest treatments, ensuring crop preservation throughout the entire agricultural cycle. Beyond fungicides, they also produce and market a selection of herbicides and insecticides, catering to a broader spectrum of crop protection needs.
Beyond the core agricultural market, Astec LifeSciences also produces specialty chemicals. This diversification allows the company to tap into different industries, further enhancing its revenue streams. The incorporation of a food additive and wood preservative product line suggests a strategic expansion aimed at leveraging their chemical expertise into related sectors. This diversification strategy mitigates reliance on any single product category and contributes to the company's overall financial stability.
A key aspect of Astec LifeSciences' business strategy is its commitment to export markets. The company actively engages in international trade, supplying its products to global customers. This international presence positions Astec LifeSciences as a key player in the broader agrochemical market, enhancing its visibility and generating additional revenue streams. Established in 1994 and headquartered in Mumbai, India, Astec LifeSciences Limited operates as a subsidiary of Godrej Agrovet Limited, benefiting from the larger parent company's resources and market expertise.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Bhagiradha Chemicals & Industries (BHAGCHEM) Share PricePeer
- Bharat Rasayan (BHARATRAS) Share PricePeer
- Dhanuka Agritech (DHANUKA) Share PricePeer
- Dharmaj Crop Guard (DHARMAJ) Share PricePeer
- Heranba Industries (HERANBA) Share PricePeer
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about Astec LifeSciences Limited (ASTEC).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Astec LifeSciences Limited (ASTEC)?
The current share price of Astec LifeSciences Limited (ASTEC) is ₹598.80. Today, the stock has gained by ₹6.10 (1.03%), trading in a range of ₹584.25 to ₹608.90. The stock opened at ₹590.00 with a trading volume of 18,905 shares.
02Is Astec LifeSciences Limited stock a good investment for long-term?
Astec LifeSciences Limited can be considered for long-term investment based on several factors. The company has a market capitalization of ₹1,341.43 Cr., P/E ratio of -20.22, ROE of -25.2%, and ROCE of -5.45%. The dividend yield stands at 0%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Astec LifeSciences Limited stock?
The 52-week high price of Astec LifeSciences Limited (ASTEC) is ₹941.75, while the 52-week low is ₹513.40. Currently trading at ₹598.80, the stock is 16.63% above its 52-week low and 36.42% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Astec LifeSciences Limited stock at the current price?
Whether to buy Astec LifeSciences Limited stock at ₹598.80 depends on multiple factors. The stock is currently trading with a P/E ratio of -20.22 and P/B ratio of 3.45. Today's performance shows a gain of 1.03%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Astec LifeSciences Limited and when is the next dividend?
Astec LifeSciences Limited offers a dividend yield of 0%, which means for every ₹100 invested at the current price of ₹598.80, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Astec LifeSciences Limited?
Astec LifeSciences Limited's key financial metrics include: P/E Ratio: -20.22, P/B Ratio: 3.45, ROE: -25.2%, ROCE: -5.45%, Dividend Yield: 0%, EPS: ₹-29.31, Book Value: ₹175.30, and Debt-to-Equity: 1.15. The company's market cap stands at ₹1,341.43 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Astec LifeSciences Limited stock performing today in the market?
Astec LifeSciences Limited stock opened at ₹590.00 and is currently trading at ₹598.80, showing a gain of ₹6.10 (1.03%). The intraday high is ₹608.90 and low is ₹584.25. The trading volume stands at 18,905 shares, indicating moderate market participation today.
08What is the P/E ratio of Astec LifeSciences Limited and what does it indicate?
Astec LifeSciences Limited has a Price-to-Earnings (P/E) ratio of -20.22, which means investors are willing to pay -20.22 for every ₹1 of earnings. With an EPS of ₹-29.31, this P/E ratio suggests the stock may be undervalued or facing growth challenges. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Astec LifeSciences Limited (ASTEC) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.